EDP239

DRUG2 trials

Sponsors

Enanta Pharmaceuticals, Inc

Conditions

Hepatitis CHepatitis C Virus

Phase 1

Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects

CompletedNCT01856426

Enanta Pharmaceuticals, IncHepatitis C

Start: 2013-06-30End: 2015-10-31Updated: 2016-01-29

Two-way Interaction Between Alisporivir and EDP239

CompletedNCT02173574

Enanta Pharmaceuticals, IncHepatitis C Virus

Start: 2014-08-31End: 2014-11-30Updated: 2015-01-09

Related Papers

Preclinical Profile and Clinical Efficacy of a Novel Hepatitis C Virus NS5A Inhibitor, EDP-239

Antimicrobial Agents and Chemotherapy2016-08-094 citations

Preclinical and Clinical Resistance Profile of EDP-239, a Novel Hepatitis C Virus NS5A Inhibitor

Antimicrobial Agents and Chemotherapy2016-08-093 citations